Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.69 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.69 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28569820 | 0.88 | MEN1 (0.71) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL1883373 | 0.87 | CA12 (0.71) | MEN1KMT2ANPC1POLBEPHX1 | |
| SCHEMBL28295632 | 0.85 | KCNMA1 (0.68) | MEN1KMT2APOLBNTRK1CDK19 | |
| SCHEMBL1875397 | 0.83 | MEN1 (1.00) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL1878682 | 0.83 | MEN1 (0.65) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL1882786 | 0.83 | NTRK1 (0.60) | MEN1KMT2AMAPTRAB9APOLB | |
| Triclocarban SCHEMBL68658 | 0.82 | MEN1 (1.00) | MEN1KMT2ANPC1MAPTRAB9A | |
| Triclocarban SCHEMBL30479188 | 0.82 | MEN1 (1.00) | MEN1KMT2ANPC1MAPTRAB9A | |
| Triclocarban SCHEMBL4978963 | 0.82 | MEN1 (1.00) | MEN1KMT2ANPC1MAPTRAB9A | |
| Triclocarban SCHEMBL27313500 | 0.82 | MEN1 (1.00) | MEN1KMT2ANPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | claimed |
| WO-2009054878-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | WO | claimed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2009054878-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | TP53, NUP205, ANXA5 | MEN1 2133/4885KMT2A 2664/4885NPC1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.